Biopharma in charts: Key takeaways from Q4 earnings

Biopharma in Charts aims to complement BioPharma Dive's daily news coverage with a data-driven look at a few of the top trends affecting the industry. This edition focuses on key takeaways from fourth quarter earnings, including strong returns from cancer drugs, growth drivers living up to the name, and the impact of a new U.S. tax code. Faster growth is forecast in 2018 for the biopharma industry, thanks to the recent overhaul to the U.S. tax code and attendant expectations of an uptick in M&A. So far, that narrative seems to have materialized many pharmas expect materially lower tax rates this year and splashy buys by Celgene Corp. and Sanofi SA build confidence in a dealmaking boom.